Skip to main content
Erschienen in: Obesity Surgery 6/2019

14.03.2019 | Original Contributions

Coincidental Detection of Gastrointestinal Stromal Tumors During Laparoscopic Bariatric Procedures—Data and Treatment Strategy of a German Reference Center

verfasst von: Orestis Lyros, Yusef Moulla, Matthias Mehdorn, Katrin Schierle, Robert Sucher, Arne Dietrich

Erschienen in: Obesity Surgery | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Intraoperative pathologic findings during bariatric surgery are relatively rare. Gastrointestinal stromal tumors (GISTs) are commonly located in the stomach and account for < 1% of all neoplasms of the alimentary tract. Coincidental detection of GISTs during bariatric surgery has been reported around 0.8%. We analyzed the incidence of GISTs in bariatric patients and investigated whether simultaneous resection can be oncologically adequate.

Material/Methods

A single-center retrospective study of 707 morbidly obese patients, who underwent bariatric surgery (either Roux-en-Y gastric bypass (RYGB), One Anastomosis Gastric Bypass (OAGB), or sleeve resection (LSG) between January 2012 and August 2018). Intraoperative incidental GISTs were recorded and documented for tumor size, localization, immunoreactivity, and mitotic index.

Results

Nine (1.27%) patients were identified with GISTs. Seven (78%) tumors were detected in women; mean age 55.6 (range 27–74), mean BMI 51.7 mg/m2 (range 38–71). GISTs were predominantly located in the stomach (78%) and two (22%) within the small bowel; six were found during RYGB vs. three during LSG. No abort of surgery or change of the intended procedure was necessary. All tumors (0.2–3.7 cm) were resected with disease-free surgical margins and displayed low malignancy. No adjuvant therapy was necessary.

Conclusions

The incidence of incidental GISTs in our series was higher to what has already been reported. Risk of malignancy was low and resection as part of the bariatric procedure was considered as definitive treatment. Suspicious tumors should be removed and confirmed by histology. In case of GIST histology, tumor resection with negative margins may be weighed as complete oncological treatment if there is low risk of malignancy.
Literatur
1.
Zurück zum Zitat Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.PubMed Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70–83.PubMed
2.
Zurück zum Zitat Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–41. quiz S42–4PubMedPubMedCentral Demetri GD, von Mehren M, Antonescu CR, et al. NCCN task force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(Suppl 2):S1–41. quiz S42–4PubMedPubMedCentral
3.
Zurück zum Zitat Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med. 2006;10(4):995–1013.PubMedPubMedCentral Min KW, Leabu M. Interstitial cells of Cajal (ICC) and gastrointestinal stromal tumor (GIST): facts, speculations, and myths. J Cell Mol Med. 2006;10(4):995–1013.PubMedPubMedCentral
4.
Zurück zum Zitat Yun HY, Sung R, Kim YC, et al. Regional distribution of interstitial cells of Cajal (ICC) in human stomach. Korean J Physiol Pharmacol. 2010;14(5):317–24.PubMedPubMedCentral Yun HY, Sung R, Kim YC, et al. Regional distribution of interstitial cells of Cajal (ICC) in human stomach. Korean J Physiol Pharmacol. 2010;14(5):317–24.PubMedPubMedCentral
5.
Zurück zum Zitat Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMed Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMed
6.
Zurück zum Zitat Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125(3):660–7.PubMed Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125(3):660–7.PubMed
7.
Zurück zum Zitat Mochizuki Y, Kodera Y, Ito S, et al. Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach. World J Surg. 2004;28(9):870–5.PubMed Mochizuki Y, Kodera Y, Ito S, et al. Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach. World J Surg. 2004;28(9):870–5.PubMed
8.
Zurück zum Zitat Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14.PubMed Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804–14.PubMed
9.
Zurück zum Zitat Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–105.PubMed Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–105.PubMed
10.
Zurück zum Zitat Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755–65.PubMedPubMedCentral Bhaskaran K, Douglas I, Forbes H, et al. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet. 2014;384(9945):755–65.PubMedPubMedCentral
11.
Zurück zum Zitat Park J, Morley TS, Kim M, et al. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–65.PubMedPubMedCentral Park J, Morley TS, Kim M, et al. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10(8):455–65.PubMedPubMedCentral
12.
Zurück zum Zitat Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMed Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.PubMed
13.
Zurück zum Zitat Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMed Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMed
14.
Zurück zum Zitat Raghavendra RS, Kini D. Benign, premalignant, and malignant lesions encountered in bariatric surgery. JSLS. 2012;16(3):360–72.PubMedPubMedCentral Raghavendra RS, Kini D. Benign, premalignant, and malignant lesions encountered in bariatric surgery. JSLS. 2012;16(3):360–72.PubMedPubMedCentral
15.
Zurück zum Zitat Ohanessian SE, Rogers AM, Karamchandani DM. Spectrum of gastric histopathologies in severely obese American patients undergoing sleeve gastrectomy. Obes Surg. 2016;26(3):595–602.PubMed Ohanessian SE, Rogers AM, Karamchandani DM. Spectrum of gastric histopathologies in severely obese American patients undergoing sleeve gastrectomy. Obes Surg. 2016;26(3):595–602.PubMed
16.
Zurück zum Zitat Finnell CW, Madan AK, Ternovits CA, et al. Unexpected pathology during laparoscopic bariatric surgery. Surg Endosc. 2007;21(6):867–9.PubMed Finnell CW, Madan AK, Ternovits CA, et al. Unexpected pathology during laparoscopic bariatric surgery. Surg Endosc. 2007;21(6):867–9.PubMed
17.
Zurück zum Zitat Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100(1):162–8.PubMed Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100(1):162–8.PubMed
18.
Zurück zum Zitat Sanchez BR, Morton JM, Curet MJ, et al. Incidental finding of gastrointestinal stromal tumors (GISTs) during laparoscopic gastric bypass. Obes Surg. 2005;15(10):1384–8.PubMed Sanchez BR, Morton JM, Curet MJ, et al. Incidental finding of gastrointestinal stromal tumors (GISTs) during laparoscopic gastric bypass. Obes Surg. 2005;15(10):1384–8.PubMed
19.
Zurück zum Zitat Yuval JB, Khalaileh A, Abu-Gazala M, et al. The true incidence of gastric GIST—a study based on morbidly obese patients undergoing sleeve gastrectomy. Obes Surg. 2014;24(12):2134–7.PubMed Yuval JB, Khalaileh A, Abu-Gazala M, et al. The true incidence of gastric GIST—a study based on morbidly obese patients undergoing sleeve gastrectomy. Obes Surg. 2014;24(12):2134–7.PubMed
20.
Zurück zum Zitat Crouthamel MR, Kaufman JA, Billing JP, et al. Incidental gastric mesenchymal tumors identified during laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015;11:1025–8.PubMed Crouthamel MR, Kaufman JA, Billing JP, et al. Incidental gastric mesenchymal tumors identified during laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2015;11:1025–8.PubMed
21.
Zurück zum Zitat Chiappetta S, Theodoridou S, Stier C, et al. Incidental finding of GIST during obesity surgery. Obes Surg. 2015;25(3):579–83.PubMed Chiappetta S, Theodoridou S, Stier C, et al. Incidental finding of GIST during obesity surgery. Obes Surg. 2015;25(3):579–83.PubMed
22.
Zurück zum Zitat Viscido G, Signorini F, Navarro L, et al. Incidental finding of gastrointestinal stromal tumors during laparoscopic sleeve gastrectomy in obese patients. Obes Surg. 2017;27(8):2022–5.PubMed Viscido G, Signorini F, Navarro L, et al. Incidental finding of gastrointestinal stromal tumors during laparoscopic sleeve gastrectomy in obese patients. Obes Surg. 2017;27(8):2022–5.PubMed
23.
Zurück zum Zitat Walędziak M, Różańska-Walędziak A, Kowalewski PK, et al. Bariatric surgery and incidental gastrointestinal stromal tumors—a single-center study: VSJ competition, 1st place. Wideochir Inne Tech Maloinwazyjne. 2017;12(3):325–9.PubMedPubMedCentral Walędziak M, Różańska-Walędziak A, Kowalewski PK, et al. Bariatric surgery and incidental gastrointestinal stromal tumors—a single-center study: VSJ competition, 1st place. Wideochir Inne Tech Maloinwazyjne. 2017;12(3):325–9.PubMedPubMedCentral
24.
Zurück zum Zitat Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.PubMed Søreide K, Sandvik OM, Søreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.PubMed
26.
Zurück zum Zitat Zhu CZ, Liu D, Kang WM, et al. Ghrelin and gastrointestinal stromal tumors. World J Gastroenterol. 2017;23(10):1758–63.PubMedPubMedCentral Zhu CZ, Liu D, Kang WM, et al. Ghrelin and gastrointestinal stromal tumors. World J Gastroenterol. 2017;23(10):1758–63.PubMedPubMedCentral
27.
Zurück zum Zitat Makris MC, Alexandrou A, Papatsoutsos EG, et al. Ghrelin and obesity: identifying gaps and dispelling myths. A Reappraisal In Vivo. 2017;31(6):1047–50.PubMed Makris MC, Alexandrou A, Papatsoutsos EG, et al. Ghrelin and obesity: identifying gaps and dispelling myths. A Reappraisal In Vivo. 2017;31(6):1047–50.PubMed
28.
Zurück zum Zitat Ekeblad S, Nilsson B, Lejonklou MH, et al. Gastrointestinal stromal tumors express the orexigen ghrelin. Endocr Relat Cancer. 2006;13(3):963–70.PubMed Ekeblad S, Nilsson B, Lejonklou MH, et al. Gastrointestinal stromal tumors express the orexigen ghrelin. Endocr Relat Cancer. 2006;13(3):963–70.PubMed
29.
Zurück zum Zitat Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31(1):113–20.PubMed Agaimy A, Wünsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31(1):113–20.PubMed
30.
Zurück zum Zitat von Mehren M. Management of gastrointestinal stromal tumors. Surg Clin North Am. 2016;96(5):1059–75. von Mehren M. Management of gastrointestinal stromal tumors. Surg Clin North Am. 2016;96(5):1059–75.
31.
Zurück zum Zitat Koch S, Besuch P. Gastrointestinal stromal tumors – retrospective classification of mesenchymal tumors of the gastrointestinal tract. DGHO 2003 [Abstract]. Koch S, Besuch P. Gastrointestinal stromal tumors – retrospective classification of mesenchymal tumors of the gastrointestinal tract. DGHO 2003 [Abstract].
32.
Zurück zum Zitat Kindblom LG, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)–a population-based study of 600 cases. Ann Oncol. 2002;13(Suppl 5):157. Abstract 5770 Kindblom LG, Meis-Kindblom J, Bümming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST)–a population-based study of 600 cases. Ann Oncol. 2002;13(Suppl 5):157. Abstract 5770
33.
Zurück zum Zitat Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005;103(4):821–9.PubMed Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer. 2005;103(4):821–9.PubMed
34.
Zurück zum Zitat Tryggvason G, Gíslason HG, Magnússon MK, et al. Gastrointestinal stromal tumors in Iceland, 1990—2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117(2):289–93.PubMed Tryggvason G, Gíslason HG, Magnússon MK, et al. Gastrointestinal stromal tumors in Iceland, 1990—2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer. 2005;117(2):289–93.PubMed
35.
Zurück zum Zitat Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68.PubMed Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29(1):52–68.PubMed
36.
Zurück zum Zitat Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17(Suppl 10):x280–6.PubMed Joensuu H. Gastrointestinal stromal tumor (GIST). Ann Oncol. 2006;17(Suppl 10):x280–6.PubMed
37.
Zurück zum Zitat Stiles ZE, Rist TM, Dickson PV, et al. Impact of body mass index on the short-term outcomes of resected gastrointestinal stromal tumors. J Surg Res. 2017;217:123–30.PubMed Stiles ZE, Rist TM, Dickson PV, et al. Impact of body mass index on the short-term outcomes of resected gastrointestinal stromal tumors. J Surg Res. 2017;217:123–30.PubMed
38.
Zurück zum Zitat Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862–70.PubMedPubMedCentral Hakimi AA, Furberg H, Zabor EC, et al. An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. J Natl Cancer Inst. 2013;105(24):1862–70.PubMedPubMedCentral
39.
Zurück zum Zitat Hines RB, Shanmugam C, Waterbor JW, et al. Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer. 2009;115(24):5798–806.PubMedPubMedCentral Hines RB, Shanmugam C, Waterbor JW, et al. Effect of comorbidity and body mass index on the survival of African-American and Caucasian patients with colon cancer. Cancer. 2009;115(24):5798–806.PubMedPubMedCentral
40.
Zurück zum Zitat Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88(8):642–6.PubMedPubMedCentral Brunner AM, Sadrzadeh H, Feng Y, et al. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013;88(8):642–6.PubMedPubMedCentral
41.
Zurück zum Zitat Nonaka K, Ban S, Hiejima Y, et al. Status of the gastric mucosa with endoscopically diagnosed gastrointestinal stromal tumor. Diagn Ther Endosc. 2014;2014:429761.PubMedPubMedCentral Nonaka K, Ban S, Hiejima Y, et al. Status of the gastric mucosa with endoscopically diagnosed gastrointestinal stromal tumor. Diagn Ther Endosc. 2014;2014:429761.PubMedPubMedCentral
42.
Zurück zum Zitat Gagner M. Comment on: gastric mesenchymal tumors as incidental findings during Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2018;14(1):28–9.PubMed Gagner M. Comment on: gastric mesenchymal tumors as incidental findings during Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2018;14(1):28–9.PubMed
43.
Zurück zum Zitat Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up Ann 2PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv267. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up Ann 2PG, Abecassis N, Aro HT, et al. Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Supplement_4):iv267.
44.
Zurück zum Zitat Huang Z, Li Y, Zhao H, et al. Prognositic factors and clinicopathologic characteristics of small gastrointestinal stromal tumor of the stomach: a retrospective analysis of 31 cases in one center. Cancer Biol Med. 2013;10(3):165–8. Huang Z, Li Y, Zhao H, et al. Prognositic factors and clinicopathologic characteristics of small gastrointestinal stromal tumor of the stomach: a retrospective analysis of 31 cases in one center. Cancer Biol Med. 2013;10(3):165–8.
45.
Zurück zum Zitat D’Ambrosio L, Palesandro E, Boccone P, et al. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. Eur J Cancer. 2017;78:122–32.PubMed D’Ambrosio L, Palesandro E, Boccone P, et al. Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. Eur J Cancer. 2017;78:122–32.PubMed
Metadaten
Titel
Coincidental Detection of Gastrointestinal Stromal Tumors During Laparoscopic Bariatric Procedures—Data and Treatment Strategy of a German Reference Center
verfasst von
Orestis Lyros
Yusef Moulla
Matthias Mehdorn
Katrin Schierle
Robert Sucher
Arne Dietrich
Publikationsdatum
14.03.2019
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 6/2019
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-019-03782-y

Weitere Artikel der Ausgabe 6/2019

Obesity Surgery 6/2019 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Real-World-Daten sprechen eher für Dupilumab als für Op.

14.05.2024 Rhinosinusitis Nachrichten

Zur Behandlung schwerer Formen der chronischen Rhinosinusitis mit Nasenpolypen (CRSwNP) stehen seit Kurzem verschiedene Behandlungsmethoden zur Verfügung, darunter Biologika, wie Dupilumab, und die endoskopische Sinuschirurgie (ESS). Beim Vergleich der beiden Therapieoptionen war Dupilumab leicht im Vorteil.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.